1.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
by van Vollenhoven, Ronald F
Annals of the rheumatic diseases, 2014, Vol.73 (6), p.958-967
2.
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease
by Sands, Bruce E
Gut, 2013, Vol.62 (9), p.1288-1294
3.
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data
by Bonthapally, Vijayveer
Current medical research and opinion, 2015, Vol.31 (5), p.993-1001
4.
Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?
by Tang, Ting Seng, MBBS
Journal of allergy and clinical immunology, 2014, Vol.133 (6), p.1615-1625.e1
5.
Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis
by Pinto-Peñaranda, Luis Fernando
Clinical rheumatology, 2015, Vol.34 (5), p.897-903
6.
Ulcerative colitis
by Ungaro, Ryan, MD
The Lancet (British edition), 2016, Vol.389 (10080), p.1756-1770
7.
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
by Fry, Terry J
Nature medicine, 2018, Vol.24 (1), p.20-28
8.
Crohn's disease
by Torres, Joana, MD
The Lancet (British edition), 2016, Vol.389 (10080), p.1741-1755
9.
Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease
by Shah, S. C.
Alimentary pharmacology & therapeutics, 2016, Vol.43 (3), p.317-333
10.
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial
by Paramsothy, Sudarshan, MD
The Lancet (British edition), 2017, Vol.389 (10075), p.1218-1228
11.
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
by Nieman, Lynnette K
The journal of clinical endocrinology and metabolism, 2015, Vol.100 (8), p.2807-2831
12.
A safe and potent anti-CD19 CAR T cell therapy
by Ying, Zhitao
Nature medicine, 2019, Vol.25 (6), p.947-953
13.
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
by Smolen, Josef S Josef S
Annals of the rheumatic diseases, 2015, Vol.75 (1), p.3-15
14.
Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates
by Schoels, Monika M
Annals of the rheumatic diseases, 2015, Vol.74 (12), p.e67-e67
15.
Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
by Humrich, Jens Y
Annals of the rheumatic diseases, 2015, Vol.74 (4), p.791-792
16.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase...
by Feagan, Brian G, Prof
The Lancet (British edition), 2017, Vol.389 (10080), p.1699-1709
17.
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
by Brudno, Jennifer N
Nature medicine, 2020, Vol.26 (2), p.270-280
18.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
by Colombel, Jean-Frederic
The Lancet (British edition), 2017, Vol.390 (10114), p.2779-2789
19.
Rituximab for IgG4-related disease: a prospective, open-label trial
by Carruthers, Mollie N
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.1171-1177
20.
Vaginal microbiome transplantation in women with intractable bacterial vaginosis
by Lev-Sagie, Ahinoam
Nature medicine, 2019, Vol.25 (10), p.1500-1504
